[go: up one dir, main page]

BR9713055A - Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina - Google Patents

Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina

Info

Publication number
BR9713055A
BR9713055A BR9713055-9A BR9713055A BR9713055A BR 9713055 A BR9713055 A BR 9713055A BR 9713055 A BR9713055 A BR 9713055A BR 9713055 A BR9713055 A BR 9713055A
Authority
BR
Brazil
Prior art keywords
neurotrophin
composition
recombinant human
neurotrophine
purifying
Prior art date
Application number
BR9713055-9A
Other languages
English (en)
Inventor
Luois E Burton
Charles H Schmelzer
Joanne T Beck
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9713055A publication Critical patent/BR9713055A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

<B>"PROCESSO PARA ISOLAR UMA NEUROTROFINA HUMANA RECOMBINANTE, COMPOSIçãO DE NEUROTROFINA E PROCESSO PARA PURIFICAR UMA NEUROTROFINA"<D>. A presente invenção se refere a métodos para purificação de neurotrofinas em larga escala, incluindo NGF maduro, adequadas para utilização clínica. Os métodos oferecem meios para separar as neurotrofinas das várias formas menos desejáveis, mal processadas, dobradas incorretamente, em tamanho, glicosiladas, ou em carga. São também fornecidas composições de neurotrofinas, incluindo NGF maduro, substancialmente livres dessas variantes.
BR9713055-9A 1996-11-15 1997-11-14 Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina BR9713055A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3083896P 1996-11-15 1996-11-15
US4785597P 1997-05-29 1997-05-29
PCT/US1997/021068 WO1998021234A2 (en) 1996-11-15 1997-11-14 Purification of neurotrophins

Publications (1)

Publication Number Publication Date
BR9713055A true BR9713055A (pt) 2000-04-04

Family

ID=26706516

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713055-9A BR9713055A (pt) 1996-11-15 1997-11-14 Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina

Country Status (21)

Country Link
US (5) US6005081A (pt)
EP (1) EP0942930B1 (pt)
JP (3) JP4671372B2 (pt)
KR (1) KR100554332B1 (pt)
CN (1) CN1268639C (pt)
AT (1) ATE371670T1 (pt)
AU (1) AU729459B2 (pt)
BR (1) BR9713055A (pt)
CA (1) CA2268747A1 (pt)
CZ (1) CZ300296B6 (pt)
DE (1) DE69738074T2 (pt)
EA (1) EA002349B1 (pt)
ES (1) ES2293662T3 (pt)
HU (1) HU222666B1 (pt)
ID (1) ID26697A (pt)
IL (2) IL129851A0 (pt)
NO (1) NO327149B1 (pt)
NZ (1) NZ335207A (pt)
PL (1) PL191400B1 (pt)
TR (1) TR199901734T2 (pt)
WO (1) WO1998021234A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9713055A (pt) * 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
WO1999027361A1 (en) * 1997-11-20 1999-06-03 Esa, Inc. Electrochemical analysis system
SI1308455T1 (sl) * 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
DE60141657D1 (de) 2000-03-27 2010-05-06 Genetics Inst Llc Verfahren zur Reinigung von stark anionischen Proteinen
DE60213248T2 (de) * 2001-06-05 2006-11-30 Genetics Institute, LLC, Cambridge Verfahren zur reinigung hochanionischer proteine
EP1456233A4 (en) * 2001-06-15 2006-06-21 Queensland Bioproc Technology ORMEAU HEMOCYANINE AND METHOD FOR PURIFICATION THEREOF
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
AU2003902066A0 (en) * 2003-05-01 2003-05-15 Norika Holdings Extraction process for a pharmaceutical product
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
EP1538201A1 (en) * 2003-12-02 2005-06-08 F.Hoffmann-La Roche Ag Method for the recombinant production and purification of protein kinases
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
WO2005103087A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
JP4944112B2 (ja) 2005-08-26 2012-05-30 アレス トレーディング ソシエテ アノニム グリコシル化されたインターフェロンベータの調製方法
US8604175B2 (en) 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
CN100419422C (zh) * 2005-12-12 2008-09-17 北京三诺佳邑生物技术有限责任公司 测定神经生长因子含量的方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CN106589132B (zh) 2005-12-20 2022-03-29 布里斯托尔-迈尔斯斯奎布公司 组合物和用于生产组合物的方法
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
WO2007088476A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
US9790538B2 (en) * 2013-03-07 2017-10-17 Apdn (B.V.I.) Inc. Alkaline activation for immobilization of DNA taggants
US10741034B2 (en) 2006-05-19 2020-08-11 Apdn (B.V.I.) Inc. Security system and method of marking an inventory item and/or person in the vicinity
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN103554215B (zh) 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
WO2010075535A1 (en) * 2008-12-23 2010-07-01 Regents Of The University Of Minnesota Neurotrophins and uses thereof
JP5695384B2 (ja) 2009-10-05 2015-04-01 花王株式会社 毛髪形状感受性遺伝子
JP5699429B2 (ja) * 2009-12-18 2015-04-08 東ソー株式会社 Ｆｃレセプターの精製方法
CN102666568B (zh) 2009-12-18 2015-12-09 杰特有限公司 纯化多肽的方法
US9447466B2 (en) 2010-06-25 2016-09-20 Nippon Zoki Pharmaceutical Co., Ltd. Method for determination or evaluation of test substance
CN102898514B (zh) * 2011-07-28 2015-04-29 中国人民解放军军事医学科学院生物工程研究所 重组人神经生长因子缺失突变体及其制备方法和用途
EP2594295A1 (en) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nerve implants based on a compacted biomaterial containing cells
US9297032B2 (en) 2012-10-10 2016-03-29 Apdn (B.V.I.) Inc. Use of perturbants to facilitate incorporation and recovery of taggants from polymerized coatings
US9266370B2 (en) 2012-10-10 2016-02-23 Apdn (B.V.I) Inc. DNA marking of previously undistinguished items for traceability
US9963740B2 (en) 2013-03-07 2018-05-08 APDN (B.V.I.), Inc. Method and device for marking articles
WO2015054188A1 (en) 2013-10-07 2015-04-16 Apdn (B.V.I), Inc. Multimode image and spectral reader
CN103880943A (zh) * 2014-01-20 2014-06-25 厦门北大之路生物工程有限公司 一种rhNGF成熟肽的制备方法
US10745825B2 (en) 2014-03-18 2020-08-18 Apdn (B.V.I.) Inc. Encrypted optical markers for security applications
EP3119610B1 (en) 2014-03-18 2024-05-22 APDN (B.V.I.) Inc. Encrypted optical markers for security applications
CN104195160A (zh) * 2014-08-08 2014-12-10 厦门北大之路生物工程有限公司 一种以Pro-BDNF的形式制备人脑源性神经营养因子的方法
US10760182B2 (en) 2014-12-16 2020-09-01 Apdn (B.V.I.) Inc. Method and device for marking fibrous materials
CN106279397A (zh) * 2015-06-09 2017-01-04 舒泰神（北京）生物制药股份有限公司 一种神经生长因子的提取方法
EP3442719B1 (en) 2016-04-11 2021-09-01 APDN (B.V.I.) Inc. Method of marking cellulosic products
CN106478801A (zh) * 2016-10-10 2017-03-08 未名生物医药有限公司 一种从哺乳动物细胞培养物中分离重组人神经生长因子的方法
US10995371B2 (en) 2016-10-13 2021-05-04 Apdn (B.V.I.) Inc. Composition and method of DNA marking elastomeric material
WO2018156352A1 (en) 2017-02-21 2018-08-30 Apdn (B.V.I) Inc. Nucleic acid coated submicron particles for authentication
GB201705955D0 (en) * 2017-04-13 2017-05-31 Cell Guidance Systems Ltd Delivery method
CN107973848B (zh) * 2017-12-28 2020-10-16 未名生物医药有限公司 一种从混合物中分离天然序列神经生长因子的方法
CN108239146A (zh) * 2018-03-26 2018-07-03 江苏中新医药有限公司 一种高纯度rhNGF的制备方法
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
CN108467429A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 疏水层析动态清除重组人神经生长因子前体的方法
WO2019207106A1 (en) * 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神（北京）生物制药股份有限公司 一种测定神经生长因子纯度的方法
CN114380901A (zh) * 2021-12-31 2022-04-22 华东理工大学 蛋白纳米粒子的制备方法、所得蛋白纳米粒子及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407744A (en) * 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4565785A (en) * 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
US4673641A (en) * 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
DK161152C (da) * 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4795706A (en) * 1985-01-31 1989-01-03 Eli Lilly And Company Novel expression control sequences
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5082774A (en) * 1988-08-30 1992-01-21 The General Hospital Corporation Recombinant human nerve growth factor
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor
DK0414151T3 (da) * 1989-08-21 1995-05-22 Takeda Chemical Industries Ltd Humane nervevæskstfaktorproteiner og fremstilling deraf
JPH04128300A (ja) * 1989-08-21 1992-04-28 Takeda Chem Ind Ltd ヒト神経成長因子蛋白質およびその製造法
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5702906A (en) * 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
DE69220259T2 (de) * 1991-02-18 1997-11-13 Takeda Chemical Industries Ltd Verfahren zur Herstellung von menschlichem NGF-2
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
NZ243084A (en) * 1991-06-12 1995-08-28 Regeneron Pharma Production and recovery of recombinant neurotrophins, genes for a modified lamb signal sequence, fusion genes and plasmids
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
JPH05211887A (ja) * 1992-01-31 1993-08-24 Hitachi Ltd 神経成長因子の生産方法
US5349055A (en) * 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
BR9713055A (pt) * 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina

Also Published As

Publication number Publication date
NO992353L (no) 1999-07-09
AU729459B2 (en) 2001-02-01
KR20000053297A (ko) 2000-08-25
EP0942930B1 (en) 2007-08-29
ID26697A (id) 2001-02-01
PL333460A1 (en) 1999-12-20
US6423831B1 (en) 2002-07-23
US6184360B1 (en) 2001-02-06
JP2007302679A (ja) 2007-11-22
JP2009040786A (ja) 2009-02-26
PL191400B1 (pl) 2006-05-31
HUP9903947A2 (hu) 2000-03-28
EA002349B1 (ru) 2002-04-25
US6812330B2 (en) 2004-11-02
TR199901734T2 (xx) 2000-01-21
EA199900436A1 (ru) 2000-02-28
JP2001503779A (ja) 2001-03-21
HU222666B1 (hu) 2003-09-29
ES2293662T3 (es) 2008-03-16
ATE371670T1 (de) 2007-09-15
AU5444898A (en) 1998-06-03
US6953844B2 (en) 2005-10-11
CZ166699A3 (cs) 1999-10-13
KR100554332B1 (ko) 2006-02-24
CN1237184A (zh) 1999-12-01
CA2268747A1 (en) 1998-05-22
DE69738074D1 (de) 2007-10-11
US20020137893A1 (en) 2002-09-26
WO1998021234A2 (en) 1998-05-22
NZ335207A (en) 2000-09-29
US6005081A (en) 1999-12-21
IL129851A0 (en) 2000-02-29
JP4881234B2 (ja) 2012-02-22
IL129851A (en) 2006-12-10
HUP9903947A3 (en) 2001-03-28
US20040138431A1 (en) 2004-07-15
WO1998021234A3 (en) 1998-07-23
NO992353D0 (no) 1999-05-14
NO327149B1 (no) 2009-05-04
CZ300296B6 (cs) 2009-04-15
CN1268639C (zh) 2006-08-09
JP4671372B2 (ja) 2011-04-13
DE69738074T2 (de) 2008-05-21
EP0942930A2 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
BR9713055A (pt) Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
ATE226960T1 (de) Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
ATE173935T1 (de) Verfahren zur isolierung und reinigung von rezeptoren für transferrin und lactoferrin von bakterien und herstellung von impfstoffen, die sie enthalten
BRPI0410685A (pt) processos de purificação de 1,3-propanodiol e composições
DE69524365D1 (de) Verfahren zur Isolierung und Reinigung von 2&#39;-Deoxy-2&#39;,2&#39;-difluornucleosiden
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
FI973059A7 (fi) Menetelmä peryleeni-3,4-dikarboksyylihappoimidien valmistamiseksi ja p uhdistamiseksi
NO993227L (no) Utvinning av sekundær etylenström fra en etylenrensingsprosess
EP0767657A4 (en) NOVEL PROCESS FOR THE PRODUCTION OF KNOWN AND NEW NUCLEOSIDES, MODIFIED IN THE 2 &#39;POSITION BY INTRAMOLECULAR NUCLEOPHILIC DISPLACEMENT
DE69606583D1 (de) Verfahren zur Herstellung von sorbierenden Zusammenstellungen
DE69606582D1 (de) Verfahren zur Herstellung von sorbierenden Zusammenstellungen
FI931332A0 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
NO993151D0 (no) FremgangsmÕte for fremstilling av renset dimer av benavledet faktor
DE69729041D1 (de) Verfahren zur Herstellung und Reinigung von Cyclisch-Estern
ZA971998B (en) Purification method.
WO2015080509A1 (ko) 다베포에틴 알파의 정제 방법
DE69517548D1 (de) Verfahren zur Herstellung von substituierten Aminen und Verfahren zur Reinigung von ihren Zwischenprodukten
CA2145169A1 (en) A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use
ATE305978T1 (de) Verfahren zur reinigung von s-adenosyl-l- methionin und zur herstellung von pharmazeutisch verträglichen salzen davon
DE59404072D1 (de) Verfahren zur Herstellung von alpha,omega-Dicarbonsäurediestern
WO1999052947A3 (en) TRANSFERRIN RECEPTOR GENES OF $i(MORAXELLA)
BR9408613A (pt) Forma purificada de estreptograminas utilização de um composto cocristalizado processo de preparação de forma purificada de estreptograminas processo de purificação de um componente minorit rio do grupo a das estreptograminas componente purificado do grupo a das estreptograminas utilização de um ou vários componentes do grupo a das estreptograminas composto cocristalizados e composição farmacéutica
DE69716203D1 (de) Verfahren zur Herstellung von hochreinem 1,3-Dialkyl-2-imidazolidinon

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: EM CONJUNTO COM A REFERIDA MANIFESTACAO, A REQUERENTE APRESENTOU UM NOVO QUADRO REIVINDICATORIO, CONTENDO 28 ( VINTE OITO )REIVINDICACOES. NO ENTANTO, NAO HOUVE O PAGAMENTO DA TAXA CORRESPONDENTE AO VALOR DAS REIVINDICACOES EXCEDENTES.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37 DA LPI, INDEFIRO O PRESENTE PEDIDO UMA VEZ QUE: AS REIVINDICACOES 1-25 NAOATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O, COMBINADO COM ART. 13 DA LPI).

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.